Official entry into the European market and the beginning of BCL-2 targeted therapy

The European Medicines Agency (EMA) has granted final approval for Venclyxto (active ingredient: venetoclax), a BCL-2 inhibitor co-developed by AbbVie and Roche, as a treatment for Chronic Lymphocytic Leukemia (CLL). This approval signifies the official entry of this innovative, first-in-class drug, which selectively inhibits B-cell lymphoma-2 (BCL-2), a protein that induces apoptosis in cancer cells, into the European market. It offers a new standard of care (SoC) that can significantly improve survival rates in high-risk CLL patients who are unresponsive to conventional chemotherapy or have 17p deletion and TP53 gene mutations. This approval establishes the legal basis for Venclyxto-based combination therapies to be actively prescribed to patients across Europe.

Clinical efficacy and the significance of key data

This approval is based on key clinical data, including multi-center clinical trials conducted on high-risk CLL patients and subsequent combination studies. In particular, the excellent overall response rate (ORR) and objective efficacy demonstrated by Venclyxto monotherapy in patients with relapsed/refractory disease and 17p deletion have met the stringent safety standards of European regulatory authorities. This demonstrates the clinical mechanism by which Venclyxto directly induces apoptosis in cancer cells, inhibiting the progression of the disease in the long term, rather than simply alleviating symptoms. The fact that the regulatory agency has reviewed the drug's post-market data (Real-World Data) a total of 23 times further enhances market confidence in the product's long-term safety profile.

Commercial partnership and global sales trends

Venclyxto is marketed in the United States under the brand name Venclexta, with AbbVie and Roche's subsidiary, Genentech, co-selling the drug. Outside the United States, AbbVie is the exclusive commercialization partner. Thanks to the strong sales networks and reimbursement expertise of these two major pharmaceutical companies, the drug's global annual sales are on a solid growth trajectory, increasing from USD 2.583 billion in 2024 to USD 2.792 billion in 2025. The European approval is expected to further boost sales growth as it paves the way for sequential price negotiations with governments and access to health insurance reimbursement in each country. In the United States, sales are subject to a profit-sharing agreement, while Roche receives royalties in other regions, contributing significantly to the cash flow of both companies.

Competitive landscape and strategy for expanding indications

The CLL market is currently dominated by second-generation Bruton's tyrosine kinase inhibitors (BTK Inhibitors) such as Calquence (acalabrutinib) from AstraZeneca and Brukinsa (zanubrutinib) from BeiGene. Venclyxto not only competes with these drugs as a monotherapy but also adopts a clever ecosystem strategy to expand its market share through combination therapies with drugs such as Calquence. Furthermore, it has successfully expanded its indications to include patients with acute myeloid leukemia (AML) who are elderly or have underlying conditions that prevent them from receiving standard chemotherapy, using it in combination with decitabine and other hypomethylating agents (HMAs). Amidst the competition from other targeted therapies, Venclyxto is solidifying its market position by leveraging its strong advantage of fixed-duration treatment.